Similar work by Ennishi et al. showed that a “double-hit gene expression signature” (DHITsig; captured by the DLBCL90 NanoString assay) can be used to identify cases of GCB-type DLBCL that share the same aggressive underlying biology exhibited by most GCB-type DLBCL tumors with MYC and BCL2 rearrangements [70]. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.